Kyverna Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
KYTX$5.08-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(39,728) | $(44,635) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Stock-based compensation | 3,171 | 2,161 |
| Accretion of discounts on available-for-sale marketable securities | (730) | (2,110) |
| Non-cash lease expense | 619 | 704 |
| Depreciation and amortization expense | 351 | 501 |
| Non-cash interest expense | 114 | — |
| Impairment of capitalized software | — | 648 |
| Changes in assets and liabilities: | ||
| Prepaid expense and other current assets | 66 | (380) |
| Other non-current assets | (5) | (515) |
| Accounts payable | 6,275 | 3,784 |
| Accrued compensation | (6,876) | (1,804) |
| Other accrued expenses and current liabilities | (4,351) | (2,306) |
| Operating lease liability | (503) | (963) |
| Net cash used in operating activities | (41,597) | (44,915) |
| Cash flows from investing activities | ||
| Purchases of available-for-sale marketable securities | (115,901) | (81,122) |
| Proceeds from maturities of available-for-sale marketable securities | 65,700 | 86,700 |
| Net cash provided by (used in) investing activities | (50,201) | 5,578 |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options | 243 | 3 |
| Principal paid on finance lease liabilities | (86) | (341) |
| Payments for offering costs | (69) | (76) |
| Taxes paid related to net share settlement of restricted stock units | (189) | — |
| Net cash used in financing activities | (101) | (414) |
| Net decrease in cash and cash equivalents and restricted cash | (91,899) | (39,751) |
| Cash, cash equivalents and restricted cash, at beginning of period | 124,644 | 97,173 |
| Cash, cash equivalents and restricted cash, at end of period | $32,745 | $57,422 |
| Reconciliation of cash, cash equivalents and restricted cash to statement of financial position | ||
| Cash and cash equivalents | 32,194 | 56,865 |
| Restricted cash | 551 | 557 |
| Cash, cash equivalents and restricted cash at end of period | $32,745 | $57,422 |
| Supplemental disclosure for non-cash investing and financing activities | ||
| Unpaid deferred offering costs included in accounts payable and other accrued expenses and current liabilities | $123 | $217 |
| Right-of-use asset obtained in exchange for operating and finance lease liability | $5,243 | $— |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $568 | $19 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.